ArticleClinical immunology (Orlando, Fla.)2008
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.
Article in Clinical immunology (Orlando, Fla.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed, 1 synthesis or guideline pooled it, 547 citations in OpenAlex.
- Pooled it
- Clinical Potential of Novel Microbial Therapeutic LP51 Based on Xerosis-Microbiome Index.Cells · 2024Trial
- IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.The Journal of investigative dermatology · 2020Trial
- Lipid abnormalities in atopic skin are driven by type 2 cytokines.JCI insight · 2018Trial
- Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.Current therapeutic research, clinical and experimental · 2026Review
- The potential effects, mechanisms and translational perspectives of natural products in the treatment of atopic dermatitis.Chinese medicine · 2026Review
- Article
- Design, Synthesis, and Biological Evaluation of Novel Vinyl Selenone Derivatives as Potent Nrf2 Activators for Atopic Dermatitis.Journal of medicinal chemistry · 2026Article
- Dysbiosis in the Pathogenesis of Atopic Dermatitis.The Journal of dermatology · 2026Review
- The neuro-immune insights of itch: peripheral mechanisms and central glial contributions.Cellular & molecular biology letters · 2026Review
- Comparative analysis of candidate gene expression in Asian atopic dermatitis and psoriasis: identification of shared and distinct molecular features.Frontiers in medicine · 2026Article
- Itching, Ionic Channels, Immune System, Magnesium and Antioxidants.Clinical, cosmetic and investigational dermatology · 2026Review
- Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors.Frontiers in immunology · 2026Review
- Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action.The Journal of investigative dermatology · 2025Review
- Article
- UV-A Radiation Impairs Sebaceous-Gland-Related Skin Barrier Function by Inducing Inflammation and Altering Intracellular Sebum-Like Lipid Composition.Journal of cosmetic dermatology · 2025Article
- Anti-Inflammatory Activity of Compounds Isolated fromInternational journal of molecular sciences · 2025Article
- Updated insights into the molecular pathogenesis of canine atopic dermatitis.Veterinary dermatology · 2025Review
- Effect of Particulate Matter in Atopic Dermatitis through HDACs and Filaggrin Alteration.Journal of microbiology and biotechnology · 2025Article
- The Role of Skin Dysbiosis and Quorum Sensing in Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2025Review
178 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Atopic dermatitis (AD) is characterized by a defective skin barrier which allows increased allergen and pathogen penetration. Loricrin (LOR) and involucrin (IVL) are proteins important for skin barrier formation and integrity. In this study, we demonstrate that the gene and protein expression of LOR and IVL is significantly decreased in involved (LOR: p<0.001; IVL: p<0.001) and uninvolved (LOR: p<0.001; IVL: p<0.001) skin of AD subjects, as compared to skin from healthy subjects. Using primary keratinocytes, we further demonstrate the down-regulatory effect of IL-4 and IL-13--which are over-expressed in the skin of AD patients--on LOR and IVL expression in keratinocytes. Additionally, skin biopsies from signal transducer and activator of transcription (STAT)-6 transgenic mice were deficient in the expression and production of LOR and IVL. This study suggests that Th2 cytokines inhibit expression of LOR and IVL through a STAT-6 dependent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.